Skip to main content
. 2008 Mar;10(3):223–234. doi: 10.1593/neo.07916

Figure 4.

Figure 4

Uptake of trastuzumab-modified and PEGylated nanoparticles with and without ASOs into HER2-positive and -negative breast cancer cell lines. Graphical summary of time-dependent uptake of trastuzumab-modified and PEGylated nanoparticles with and without ASOs into (A) BT-474, (B) SK-BR-3, and (C) MCF-7 cells (n = 3, mean ± SD).